Loading clinical trials...
Loading clinical trials...
Acute Myocardial Infarction Upbound to PCI Immediately (STEMI) or in the Next Three Days (NSTEMI), and Randomized to Subcutaneous Evolocumab or Normal Strategies to Reach Guidelines LDL Objectives in the Real-world - The AMUNDSEN-real Study
Conditions
Interventions
Evolocumab 140 MG/ML
Standard of care (SOC)
Locations
1
France
ACTION Group, Institut de Cardiologie, Centre Hospitalier Universitaire Pitié Salpêtrière (APHP), UPMC
Paris, France
Start Date
September 29, 2021
Primary Completion Date
May 22, 2026
Completion Date
May 22, 2028
Last Updated
April 13, 2026
NCT07257198
NCT06438315
NCT07160491
NCT06927791
NCT06678074
NCT07478003
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions